Table 2 Breast cancer patients; clinical data according to mutational status of BRCA1/2 and TP53 genes.

From: Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service

Clinical data

Positive (n = 39)

%

Negative (n = 209)

%

p

Sex

    

0.114

Female

36

92

204

98

 

Male

3

8

5

2

 

Age at first BC

    

0.523

 < 30

7

18

21

10

 

30–39

15

38

85

41

 

40–49

9

23

49

23

 

 ≥ 50

8

21

54

26

 

Mean (SD)

39.9 (10.9)

 

42.1 (12.1)

  

Median

38

 

39

  

Laterality

    

0.007

Unilateral

28

72

188

90

 

Bilateral

11

28

21

10

 

Stage

    

0.225

Localized

13

33

83

40

 

Regional

22

56

118

56

 

Distant

2

5

5

2

 

na

2

5

3

1

 

Histology

    

1.000

IDC

37

95

188

90

 

ILC

1

3

9

4

 

Other

1

3

8

4

 

na

0

0

4

2

 

Receptor status

    

0.057

ER/PR + 

24

62

155

74

 

HER2 + 

1

3

13

6

 

TN

13

33

31

15

 

na

1

3

10

5

 

Ki-67 index

    

0.535

 ≥ 15%

32

82

152

73

 

 < 15%

2

5

21

10

 

na

5

13

36

17

 

Grade

    

0.214

1

3

8

27

13

 

2

18

46

118

56

 

3

14

36

54

26

 

na

4

10

10

5

 
  1. Positive/negative refers to the presence/absence of a pathogenic or likely pathogenic variant (PV/LPV) in BRCA1, BRCA2 or TP53 genes. SD = standard deviation. na = not available. Localized: stages 0, I or IIA. Regional: stages IIB or III. Distant: stage IV. IDC: invasive ductal carcinoma. ILC: invasive lobular carcinoma. Fisher’s exact test was applied to all variables, except for analyses of age (where T-test was applied). All p-values < 0.05 are in bold.
Back to article page